CD274 and colorectal carcinoma: Recently, immune checkpoint blockage (ICB) with monoantibody targeting programmed cell death‐1 (PD1) or programmed cell death ligand‐1 (PD‐L1) has been proved to be superior to typical chemotherapy in improving progression‐free survival (PFS) time of highly microsatellite instable or deficient mismatch repair (MSI‐H/dMMR) CRC patients, which is confirmed in a series of clinical trials, providing novel options for treatment of mCRC.[2]